Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.140
+0.010 (0.47%)
Feb 11, 2026, 4:00 PM EST - Market closed
Xenetic Biosciences Employees
Xenetic Biosciences had 2 employees as of December 31, 2024. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change (1Y)
-2
Growth (1Y)
-50.00%
Revenue / Employee
$1,429,468
Profits / Employee
-$1,578,153
Market Cap
4.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2021 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2020 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GeoVax Labs | 17 |
| VivoSim Labs | 13 |
| Genprex | 13 |
| Processa Pharmaceuticals | 10 |
| Aprea Therapeutics | 8 |
| Acurx Pharmaceuticals | 4 |
| 60 Degrees Pharmaceuticals | 3 |
| Decoy Therapeutics | 2 |
XBIO News
- 2 months ago - Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Accesswire
- 6 months ago - Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Accesswire
- 7 months ago - Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - Accesswire
- 7 months ago - Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire
- 7 months ago - Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer - Accesswire